23443-25-6

Usage

Uses

Used in Pharmaceutical Research:
4-Hydroxy-6-methoxy-1,5-naphthyridine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block for the development of new drugs with improved efficacy and selectivity.
Used in Antimalarial Applications:
4-Hydroxy-6-methoxy-1,5-naphthyridine is being studied for its potential antimalarial properties. It may act by inhibiting essential enzymes or pathways in the Plasmodium parasite, thereby disrupting its life cycle and preventing the disease transmission.
Used in Antibacterial Applications:
4-Hydroxy-6-methoxy-1,5-naphthyridine is also being investigated for its antibacterial properties. It may target specific bacterial enzymes or processes, leading to the inhibition of bacterial growth and helping in the treatment of various infections.
Used as a Fluorescent Probe for DNA Detection:
4-Hydroxy-6-methoxy-1,5-naphthyridine has potential as a fluorescent probe for detecting DNA. Its fluorescence properties can be utilized to visualize and analyze DNA structures, which can be beneficial in molecular biology research and diagnostics.
Used in the Development of New Therapeutic Agents:
The pharmacological activity of 4-Hydroxy-6-methoxy-1,5-naphthyridine makes it a promising candidate for the development of new therapeutic agents. Its unique structure and functional groups can be further modified to create novel compounds with enhanced therapeutic potential and selectivity for various diseases and conditions.

Upstream product

• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 922-67-8 propynoic acid methyl ester 
• 2033-24-1 cycl-isopropylidene malonate 
• 101-84-8 diphenylether 
• 1242446-41-8 (E)-methyl 3-(6-methoxypyridin-3-ylamin)acrylate 
• 405937-76-0 C₁₀H₁₂N₂O₃ 
• 53241-85-3 6-methoxy-4-oxo-1,4-dihydro-[1,5]naphthyridine-3-carboxylic acid 
• 25063-69-8 5-[[(6-methoxypyridin-3-yl)amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 577771-12-1 C₁₀H₁₀N₂O₃ 

Downstream Products

• 249889-68-7 8-chloro-2-methoxy-1,5-naphthyridine 
• 1431984-59-6 C₂₅H₃₀N₆O₂ 
• 1431984-60-9 C₃₀H₄₁N₇O₂ 
• 1431984-75-6 C₂₃H₂₄F₂N₆ 
• 1431984-74-5 C₂₃H₂₄F₂N₆ 
• 1431984-61-0 C₂₆H₂₈N₈O₄S 
• 1431984-62-1 C₂₃H₂₁N₅O₂ 
• 1431984-65-4 2,8-dichloro-7-(1-methyl-1H-pyrazol-4-yl)-1,5-naphthyridine 
• 1431984-85-8 C₂₅H₂₈N₆O₂ 
• 1431984-63-2 C₂₂H₂₂BrN₅O₂ 
• 1431984-64-3 C₂₄H₂₃N₇O₂ 
• 1431985-36-2 C₂₀H₁₉N₅O₂ 
• 1431985-37-3 C₂₈H₃₇N₅O₃Si 
• 1431984-55-2 C₂₂H₂₃N₅O₃ 

Relevant academic research and scientific papers

Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria

A novel 2,8-disubstituted-1,5-naphthyridine hit compound stemming from the open access Medicines for Malaria Venture Pathogen Box formed a basis for a hit-to-lead medicinal chemistry program. Structure-activity relationship investigations resulted in compounds with potent antiplasmodial activity against both chloroquine sensitive (NF54) and multidrug resistant (K1) strains of the human malaria parasite Plasmodium falciparum. In the humanized P. falciparum mouse efficacy model, one of the frontrunner compounds showed in vivo efficacy at an oral dose of 4 × 50 mg·kg-1. In vitro mode-of-action studies revealed Plasmodium falciparum phosphatidylinositol-4-kinase as the target.

SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR

Provided are a preparation and applications of a six-membered fused with six-membered heterocyclic compound, specifically, provided in the present invention is a compound as represented by formula I as follows, where the definitions of the groups are as described in the description. The compound has TRK kinase inhibiting activity and can serve as a pharmaceutical composition for treating TRK dysfunction-related diseases.

Process for Manufacturing a Naphthyridine Derivative

The invention relates to a process and synthetic intermediates that can be used for manufacturing the compound of formula (1-6) which is a synthetic intermediate useful in the preparation of antibiotic compounds.

A one-pot diazotation-fluorodediazoniation reaction and fluorine gas for the production of fluoronaphthyridines

Several synthetic routes to 7-fluoro-2-methoxy-8-methyl-1,5-naphthyridine (1) are presented, and their suitability for scale-up is discussed. The way of introducing the fluorine atom is crucial. Early routes start from commercially available fluorinated building blocks or employ F+ reagents like SelectFluor and delivered up to 70 kg of 7-fluoro-2-methoxy-1,5-naphthyridine (18). To prepare for larger scales, the focus turned to the use of HF or elemental fluorine, both one of the cheapest sources of fluorine. The first method, a one-pot diazotation-fluorodediazoniation with 6-methoxy-1,5- naphthyridin-3-amine (9) in HF gave the fluorinated naphthyridine 18 in high yield and purity without isolation of the unstable diazonium salt, the latter being a severe drawback of the related Balz-Schiemann protocol. The second method relies on the use of fluorine gas for a surprisingly selective ortho-fluorination of 6-methoxy-1,5-naphthyridin-4-ol (10).

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

PROCESS FOR MANUFACTURING A NAPHTHYRIDINE DERIVATIVE

The invention relates to a process and synthetic intermediates that can be used for manufacturing the compound of formula (1-6) which is a synthetic intermediate useful in the preparation of antibiotic compounds.

NEW COMPOUNDS

The invention relates to new naphthyridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are 8-substituted quinolines and related analogues as sirtuin-modulating compounds of Structural Formula (I) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Flexible palladium-catalysed amidation reactions for the synthesis of complex aryl amides

This Letter describes the synthesis of complex aryl amides using palladium-catalysed amidation reactions. Use of these conditions allowed for the coupling of a variety of aryl halides and triflates with a host of primary amides in high yields.